SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Strides Arcolab’s arm signs research collaboration agreement with Bio-Scaffold International

23 Oct 2013 Evaluate

Strides Arcolab’s biotech subsidiary - Stells Biopharma (previously known as Agila Biotech) has entered into Research Collaboration Agreement with Bio-Scaffold International (BSI), a Singapore based, start-up Company, to research and develop BMP and stem cell loaded 3D printed devices for various applications in Orthopaedics, Cosmetology/ Plastic and Reconstructive Surgery and Dentistry. The Research will be jointly directed by Anand Iyer, Stelis Biopharma and Margam Chandrasekaran and each Company will bear the cost of its contribution to the joint research collaboration.

BSI is a pioneer in the application of 3D printing technology for the development of novel, biocompatible scaffolds. Stelis is a cutting edge biotechnology company whose research and development efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions. Scientists from Stelis and BSI have developed a framework for initial research collaboration which would include working on multiple areas such as BMP-2/7 heterodimer loaded scaffold for orthopaedic applications and BMP2/ BMP7 loaded scaffolds for spinal fusion etc.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.  

Strides Pharma Scien Share Price

1000.70 6.80 (0.68%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×